(Received for publication November 17, 2003) In this paper we describe the establishment of an efficient visual method for screening heparanase inhibitors, and we present the results of screening 10,000 microbial culture broths. Heparanase-overexpressing stable clones of the human hepatocellular carcinoma HepG2 cells were established and used as an enzyme source. Digestion of heparan sulfate (HS) was detected using novel HS-containing tablets or SDS-polyacrylamide gel electrophoresis. This method was able to find suramin, a known heparanase inhibitor, from a library of typical enzyme inhibitors. By screening 10,000 culture broths of microorganisms (actinomycetes, fungi, and bacteria) an actinomycete strain, RK99-A234, was found to have heparanase inhibitory activity. RK-682 important roles in tumor metastasis1-5). When tumor cells spread out, they must penetrate the extracellular matrix (ECM) and the basement membrane (BM)6). At that time, tumor cells secrete matrix metalloproteases and heparanase to degrade major components of ECM and BM such as type IV collagen and heparan sulfate proteoglycans5,7).
Moreover, heparanase releases several growth factors, such as bFGF and VEGF, which bind to heparan sulfate (HS) chains in ECM and BM to cause angiogenesis8-10). Therefore, heparanase is recognized as a successful target molecule for antitumor agents.
Although the importance of heparanase has been known for more than two decades11-13), cloning of heparanase gene has not been achieved more recently because of the instability of the enzyme and the difficulties of detecting the enzyme activity14-17 Industries (Osaka, Japan). HepG2-HP-1 cells were collected with cold PBS (pH 6.2) and were subjected to three cycles of freezing and thawing. After centrifugation, the supernatant was collected as cell lysate. The mixture of solution (10mg/ml in PBS, pH 6.2) with or without reaction mixture was subjected to SDS-PAGE (20%). After an electrophoresed gel was soaked in H2O for 2 hours to remove SDS, it was stained with 0.5% Alcian blue for 1 hour and de-stained with AcOH-EtOH-H2O ( The gels were transferred to polycarbonate tubes (1.5ml) and were washed with distilled water. HepG2-HP-1 lysate distilled water, the gels were stained with 1ml of the Alcian blue solution (0.5% in AcOH-EtOH-H2O, 1:2:7) for 1 hour and de-stained with AcOH-EtOH-H2O (1:2:7) until the control gel that did not contain HS was completely destained. Quantification of the gels was carried out using the (Fig. 1, A) or vector alone were labeled HepG2-HP-# (# indicates clone number) or HepG2-Neo, respectively. The result of western blotting using anti-c-myc antibody (Fig. 1, B) showed that These results indicate that this lysate possesses HS selectivity. The effect of pH in lysate preparation was also assessed. HS degradation activity was kept up in the range of pH 5-6, but the activity disappeared at pH below 4 or over 7. The following experiments were executed using the lysate prepared by repeatedly freezing and thawing at pH 6 and containing no detergents. Alcian blue and the density of the colors was quantified.
The color density of tablets was correlated with the concentrations of HS (Fig. 3, A) . Then the tablets were incubated in the lysate of HepG2-HP-1 cells and stained with Alcian blue. In the case of HS concentration of thoroughly than with other concentrations (Fig. 3, B) . This result indicates that heparanase in the lysate of HepG2-HPand the degraded fragments of HS are excluded from the tablet. From these results, we assumed that it is possible actinomycete strain of RK99-A234 was found to have heparanase inhibitory activity. After purification of the active substance using consecutive column chromatography, the structure was identified by means of NMR and MS. The result of negative ion FAB-MS showed a strong peak at m/z 367 (M-H)-. A molecular structure was speculated by the presence of 1D-(1H and 13C) and 2D-NMR (DQF-COSY, HMQC, and HMBC). Finally the inhibitor was identified to be RK-682, which was previously identified as a protein tyrosine phosphatases and dual-specificity phosphatases inhibitor (Fig. 4, A) . The IC50 rather higher than that for VHR (Table 1) . After rational drug design using RK-682 as a lead compound, we could 
